Skip to content

A STEREOTYPED RESPONSE INDUCED BY MESCALINE IN MICE AS A MEANS OF INVESTIGATING THE PROPERTIES OF DRUGS ACTING ON THE CNS

G Maffii, E Soncin

Journal of Pharmacy and Pharmacology September 1, 1958 DOI: 10.1111/j.2042-7158.1958.tb10339.x via OpenAlex

Summary

AI-generated from the abstract

Mescaline induces a stereotyped response in mice, measured as spontaneous activity in special cages. Chlorpromazine most specifically blocks this response. Promazine, hexobarbitone, and pentobarbitone also reduce the effect at doses that do not impair motor function, while phenobarbitone has little effect. Meprobamate, mephenesin, a thiadiazole derivative (L 1458), and azacyclonol do not produce specific antagonistic effects at non-paralyzing doses. Atropine does not significantly influence the response, but morphine enhances it.

Study at a glance

Characteristics Experimental study Peer reviewed
Population Mice
Interventions Promazine Hexobarbitone Pentobarbitone Phenobarbitone Meprobamate Mephenesin L 1458 Azacyclonol Atropine Morphine
Topics Mescaline
Keywords Meprobamate Atropine Chlordiazepoxide Pharmacology
Citations 8
Key finding Chlorpromazine shows the highest specificity in blocking the stereotyped response induced by mescaline in mice.

Abstract

Abstract The effects of mescaline on spontaneous activity of mice placed in special cages have been studied. The typical response (stereotyped response) has been recorded and assessed in terms of percentage of animals showing the effect. Among drugs affecting the response chloropromazine shows the highest specificity. Promazine, hexobarbitone and pentobarbitone also show a definite but minor effect in doses that do not impair motor function. The response is little affected by phenobarbitone. Meprobamate, mephenesin and a thiadiazole derivative (L 1458) at non-paralyzing doses, and also azacyclonol, do not produce specific antagonistic effects. Nor is the effect significantly influenced by atropine, but it is enhanced by morphine.

Explore topics

Comments

No comments yet.

Log in to comment